Clinical trials: Steatosis
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals
Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders.
- Trial name
- NCT05245890
- Volunteers
- 2,000 people
- Sponsor
- Ningbo No. 1 Hospital
Nonalcoholic Steatohepatitis
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD), which is characterized by lobular inflammation and apoptosis resulting from hepatic steatosis in the absence of excessive alcohol…
- Trial name
- NCT05733897
- Testing
- hydroxychloroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Coronary Disease, Non-alcoholic Fatty Liver Disease
Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD).
- Conditions
- Coronary Disease, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques
- Trial name
- NILS-R-CHD (NCT02779946)
- Testing
- Fibro Scan, PNPLA3
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- University of Leipzig
Non-Alcoholic Fatty Liver Disease
Hepatic Urea Nitrogen Handling in Patients With NASH
The aim of the project is to investigate the metabolic regulation of the hepatic urea nitrogen handling and various cognitive functions measured by psychometric and neurophysiological tests before and after bariatric surgery in…
- Trial name
- NCT03260036
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
- Trial name
- STELLAR-3 (NCT03053050)
- Testing
- SEL
- Where
- 298 sites in United States, Argentina and 25 more
- Volunteers
- 808 people
- Sponsor
- Gilead Sciences
Obesity Prevention, Pediatric Obesity
Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project
Childhood obesity is a growing public health issue affecting millions of children worldwide, increasing the risk of metabolic and cardiovascular diseases in adulthood.
- Conditions
- Obesity Prevention, Pediatric Obesity, Trisomy 21, Down Syndrome (Trisomy 21)
- Trial name
- LiverTy (NCT06888570)
- Testing
- To evaluate fat liver content in the cases/controls population.
- Where
- Spain
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- IMDEA Food
Chronic Hepatitis C
Impact of Hepatitis C Virus Variability on Steatosis
Chronic infection by the hepatitis C virus (HCV) is a common cause of liver disease, which may progress to cirrhosis and eventually liver cancer.
- Trial name
- Viro-steatosis (NCT00843076)
- Where
- 6 sites in France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Tours
Nonalcoholic Fatty Liver Disease (NAFLD)
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty…
- Trial name
- NCT02244944
- Testing
- EZ-Urso combination therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gregory Graf, PhD
NASH
A Phase II Clinical Trial of Chiglitazar for NASH
The study is to evaluate the efficacy and safety of chiglitazar monotherapy in patients with non-clcoholic steatohepatitis (NASH).
- Trial name
- NCT05193916
- Testing
- chiglitazar sodium tablets
- Where
- 15 sites in China
- Volunteers
- 104 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Diabetes Mellitus, Non-alcoholic Fatty Liver Disease
Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD
Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat is deposited in the liver. Almost all patients also have obesity and insulin resistance (the inability of the body to effectively use insulin).
- Trial name
- FMT (NCT02496390)
- Testing
- Autologous, Allogeneic
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Metabolic-associated Fatty Liver Disease (MAFLD)
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals.
- Trial name
- NCT06798948
- Testing
- Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Lab,MD
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
- Trial name
- NCT03205150
- Testing
- LIK066
- Where
- 15 sites in United States, Argentina and 6 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Non-alcoholic Fatty Liver Disease
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.
To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.
- Trial name
- NCT04104282
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
Obesity, NAFLD
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome
Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial…
- Conditions
- Obesity, NAFLD, Fatty Liver, Pre Diabetes
- Trial name
- CALIBRATE (NCT04786418)
- Testing
- Standard of care, Low-calorie diet
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Nonalcoholic Steatohepatitis
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether low level laser therapy (LLLT) using the Erchonia VERJU and EVRL laser devices is effective in reducing aminoalanine transaminase (ALT) levels in individuals with nonalcoholic…
- Trial name
- NCT03163810
- Testing
- Erchonia Verju Laser, Erchonia EVRL Laser
- Where
- United States
- Sponsor
- Erchonia Corporation
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
The purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others.
- Conditions
- Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity
- Trial name
- NCT01104220
- Testing
- Weight loss
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type2 Diabetes, NAFLD
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes. Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown to reduce production and deposition of fat in the…
- Trial name
- NCT02964715
- Testing
- Empagliflozin
- Where
- Malaysia
- Volunteers
- 25 people
- Sponsor
- University of Malaya
Insulin Sensitivity, Fat; Liver
Race Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity
This research study will examine how ethnic/racial background, body composition (%body fat), and the location of body fat affect the ability of the hormone insulin to promote uptake of blood sugar in persons who are 19 to 45…
- Trial name
- NCT03043235
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Cardiovascular Disease, Hypercholesterolemia
Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol
The purpose of this study is to investigate the short-term effects of a reduced fat plant-based diet on biomarkers of inflammation, oxidative stress and cardiovascular risk.
- Conditions
- Cardiovascular Disease, Hypercholesterolemia, Obesity, Fatty Liver
- Trial name
- NCT01817491
- Testing
- American Heart Association Diet, Reduced Fat Vegan Diet
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Obesity
Dietary Intervention for Visceral Adiposity
The purpose of this research study is to determine whether increased intake of dietary fiber during a 12-week, low-calorie weight loss intervention affects abdominal fat change and improves cardiovascular risk factors in…
- Trial name
- DIVA-Pilot (NCT01350518)
- Testing
- Benefiber, TrueLemon
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.